InternationalUSRemember you can easily switch between MIP US and MIP International at any time

India: Novartis fights on in Gleevec battle

Novartis has now appealed to the Supreme Court in a bid to overturn the rejection of its controversial patent for Gleevec. Archana Shanker of Anand and Anand discusses the issues raised by the case

The speculation seemed to have come to an end on June 26 2009 when the Intellectual Property Appellate Board (IPAB) gave its decision on the Novartis patent application directed to the beta crystalline version of imatinib mesylate (Gleevec), refusing the patent application. Novartis then filed a special leave petition (SLP) before the Supreme Court, which has issued notice to the respondents in the matter (Union of India and others) to decide the issue of maintainability.

The facts of the Novartis pre-grant oppositions are well known and this article is only an attempt to summarise the issues and the propositions of law that have been discussed in the judgment.

By way of background, Novartis AG, a Swiss pharmaceutical company, applied for patent number 1602/MAS/1998 claiming Swiss priority of July 18 1997 for an invention directed to a "beta crystalline form of imatinib mesylate". Cancer Patient Aid Association (CPAA), NATCO Pharma, CIPLA...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here


Managing IP


ManagingIP profile

Erich Spangenberg, #AppSung, Alibaba, Jay-Z, Kanye, more monkey selfie – @mdloney's IP week

Oct 2 2015 08:18 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @sinha_sham: @ManagingIP haha. Yes. I am a lawyer too and I totally understand how it feels when that happens

Oct 2 2015 03:51 ·  reply ·  retweet ·  favourite
ManagingIP profile

@sinha_sham Yes- and specifically when the quote is used in response to a question from bench. Often can't tell if question was answered.

Oct 2 2015 03:40 ·  reply ·  retweet ·  favourite
More from the Managing IP blog

October 2015

Circuit overload: How the Federal Circuit is changing

More than half of its judges have changed in the past five years, the Supreme Court keeps smacking it down, and a flood of new PTAB appeals is coming its way. Michael Loney assesses how today’s Federal Circuit is coping

Most read articles